Description overdue on 20.03.2012

Proton pump inhibitors . Drug metabolism occurs in the gastric parietal cells, metabolic products - active sulfonamide derivatives. By reducing the stimulated and basal secretion of lansoprazole blocking the final stage of the process of secretion hydrochloric acid   regardless of the nature of the stimulus. The active component has high lipophilicity, easily penetrates the gastric parietal cells, which renders concentrating cytoprotective effects It increases the secretion of bicarbonate increases the oxygenation of the mucosa of the stomach wall. The drug has no effect on the motility of the digestive tract. The inhibitory effect increases during the first four days of application. After the abolition of the drug "rebound" increase the secretion is not registered. Lansoprazole is provided faster healing of ulcers in the duodenum. Available in capsule form.

Indications:

Lansoprazole is prescribed for   erosive and ulcerative esophagitis , Ulcerative lesions of the digestive system, Zollinger-Ellison syndrome , Ulcerative dyspepsia , As part of an integrated treatment of Helicobacter pylori eradication, in stress ulcers of the digestive tract.

Contraindications:

Lansoprazole is not applicable in malignant tumors of the digestive system, pregnancy, intolerance of the main component, breastfeeding. The elderly, with renal disease administered with caution.

Side effect:

Digestive system:   eating disorders, disorders of the chair (a combination of diarrhea   and constipation ), Nausea, candidiasis, nonspecific ulcerative colitis . hyperbilirubinemia , Increased levels of liver enzymes. Nervous system:   anxiety, depression, drowsiness, dizziness, malaise. Respiratory system: flu-like symptoms , Infections of the respiratory tract, rhinitis, pharyngitis Cough. Perhaps the development of anemia, alopecia, myalgia, exudative erythema multiforme, photosensitivity, allergies, skin rashes.

Mode of application:

Lansoprazole capsules swallowed without chewing. Ulcerative lesions of the digestive system: 30 mg once a day, the duration of therapy 2-4 weeks. Reflux esophagitis: 4 weeks to 30 mg per day. Zollinger-Ellison syndrome: the selection of the dose individually with the achievement of the basal acidity of less than 100mmol per hour. Non-ulcer dyspepsia: 2-4 weeks at 15-30 mg / day. Eradication of Helicobacter pylori: twice daily to 30 mg is recommended to be combined with antibiotics.

Special instructions:

Recommended before treatment and after treatment to carry out endoscopic examination to rule out the presence of malignancy (the drug lansoprazole can mask the symptoms, delaying the correct diagnosis).

Drug Interactions:

Lansoprazole reduces the clearance   theophylline   ten percent. The drug slows elimination Drug metabolism that occurs in the liver by microsomal oxidation system (indirect anticoagulants, phenytoin, diazepam). Lansoprazole is compatible with prednisolone, phenytoin, oral contraceptives, warfarin, propranolol , Diazepam, indomethacin, ibuprofen. Antacids reduce the rate and extent of drug absorption.